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Abstract Thiol-activated cytolysins share a conserved hydro-
phobic, Trp-rich undecapeptide that is suggested to be involved in
membrane binding and intercalation. The neutralizing mono-
clonal antibody PLY-5 recognizes all members of this toxin
family and peptide mapping assigned its epitope to the
undecapeptide motif. This antibody inhibited binding of the
toxins to host cell membranes and the epitope was no longer
available for binding when a preformed toxin/membrane complex
was tested. These results confirm the model of cytolysin binding
suggested by structural data.
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1. Introduction
Thiol-activated, pore-forming cytolysins are produced by
several species of Gram-positive bacteria (Bacillus, Clostridi-
um, Streptococcus and Listeria). All these toxins are believed
to bind to cholesterol as receptor in the host cell membranes
which subsequently leads to insertion and oligomerization. As
a consequence the membrane is permeabilized [1]. However,
besides membrane permeabilization these cytolysins exhibit
several other functions including induction of cytokine secre-
tion and other modulators of the immune system [2,3]. Thus,
most likely these cytolysins play essential roles as virulence
factors in the progression of an infection by these bacteria [4].
The di¡erent thiol-activated cytolysins share sequence ho-
mology between 40 and 70%. They have in common a well-
conserved Trp-rich undecapeptide in their C-terminal region
which also contains the unique Cys that is found in all of
these toxins. Recently, the crystal structure of perfringolysin
O (PFO), one of the members of this toxin family, was re-
solved [5]. The monomer is folded into four discontinuous
domains forming an elongated mushroom-like molecule. The
putative membrane binding domain 4 comprises the last 110
C-terminal residues which includes the conserved Trp-rich un-
decapeptide. This hydrophobic motif forms a tip at the end of
the molecule and presumably dips into the membrane to pro-
mote binding [6,7].
Monoclonal antibodies (mAbs) have been raised against
several thiol-activated cytolysins. Some of them have been
shown to neutralize hemolysis by preventing polymerization,
whereas only a few were found to interfere with binding [8^
11]. Here we report that PLY-5, a mAb that was raised
against pneumolysin (PLY), recognizes an epitope in all thi-
ol-activated cytolysins tested so far. Epitope mapping revealed
that this antibody reacts with the conserved Trp-rich motif.
Preincubation of toxins with PLY-5 prevented binding to
membranes whereas the epitope was no longer accessible after
membrane binding. These data corroborate the model ob-
tained by X-ray di¡raction [5], suggesting that the Trp-rich
motif is responsible for binding by inserting into the host cell
membrane.
2. Materials and methods
2.1. Antigens
Recombinant PLY was expressed in Escherichia coli and puri¢ed as
described [12]. Listeriolysin O (LLO) was hyperexpressed in Listeria
innocua and puri¢ed as described [9]. Perfringolysin O (PFO) and
suilysin (SLY) were obtained as described [13,14]. Streptolysin O
(SLO) was purchased from Sigma. Additional pore-forming toxins
employed in immunoblot analyses were used unpuri¢ed from bacterial
supernatants. Strains (Bacillus cereus 148, Clostridium tetani 829, Lis-
teria ivanovii 913, Listeria seeligeri, Bacillus alvei, Bacillus thuringien-
sis, Clostridium botulinum) were obtained from the Spanish Type Cul-
ture Collection and were cultured in brain-heart infusion broth. As
negative controls K-hemolysin from Staphylococcus aureus and E. coli
(both from Sigma) were used.
2.2. Antibodies
Generation of the mouse monoclonal antibody PLY-5, the polyclo-
nal rabbit anti-LLO antisera (pLLO) and a polyclonal anti-PLY anti-
serum has been described [8,9]. The neutralizing mouse mAb 2-5B
speci¢c for SLO was a generous gift of Dr. F. Hugo, Giessen, Ger-
many [10].
2.3. Immunoblot assays
For immunoblot assays 500 ng of puri¢ed toxin or 15 Wl of culture
supernatants after TCA precipitation were applied per lane and sep-
arated by SDS-PAGE. After transfer to nitrocellulose, speci¢c protein
bands were developed using the BM chemiluminescence blotting sub-
strate (POD) of Boehringer Mannheim according to the instructions
of the vendor. Primary antibodies were used at 1 Wg/ml; peroxidase-
conjugated sheep anti-mouse IgG (Fab; Boehringer Mannheim) or
goat anti-rabbit IgG (IgG; Jackson Laboratories) were used as sec-
ondary reagents.
2.4. Analyses of toxin-membrane interactions by £ow cytometry
Two assays were employed. Two hemolytic units (HU) of SLO were
incubated with 1 Wg/ml of the mAbs PLY-5 or 2-5B for 30 min at
37‡C, 50 Wl of 1.6% sheep red blood cells (SRBC) in 1% bovine serum
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albumin in phosphate-bu¡ered saline containing 0.1% NaN3 (BSA-
PBS-N3) were added and further incubated for 30 min at 37‡C. Then,
cells were washed, resuspended in BSA-PBS-N3 and stained with
FITC-conjugated anti-mouse IgG (Sigma). Alternatively, SRBC
were treated with 2 HU SLO or 4 HU LLO on ice. After washing,
toxin-SRBC complexes were incubated with either PLY-5 and 2-5B
(for SLO) or PLY-5 and polyclonal anti-LLO (for LLO). Binding of
antibodies was revealed by staining with FITC-conjugated anti-mouse
IgG or anti-rabbit IgG as secondary reagents. After staining, cells
were washed, ¢xed in 100 Wl of 1% paraformaldehyde and analyzed
using a Cytotron Absolute £ow cytometer (Ortho). At least 35 000
events were recorded per sample. Data were analyzed using WinList
(Verity Software House).
2.5. Analyses of toxin-membrane interactions by immunoblot
SRBC were washed three times with PBS and lysed with 5 mM
HEPES, pH 7.4. Membranes were washed with lysis bu¡er and fur-
ther incubated with 10 mM HEPES, pH 7.4, 130 mM KCl, 10 mM
NaCl, 3 mM MgCl2 for 1 h to allow formation of vesicular ghosts.
These were sedimented and resuspended in PBS, pH 7.4. Ghosts from
1U105 SRBC were incubated with 100 ng LLO or PLY or with the
same amount of the particular toxin that was neutralized by addition
of 1 Wg PLY-5 for 15 min at 20‡C in 200 Wl PBS. Membranes were
then sedimented by ultracentrifugation, washed and solubilized in
SDS-PAGE loading bu¡er. Toxin from the supernatant was recovered
by TCA precipitation. Subsequently, SDS-PAGE was performed on
12% polyacrylamide gels. Proteins were blotted and developed using
the polyclonal rabbit anti-LLO antiserum which also detects PLY.
2.6. Epitope mapping
A library of overlapping peptides 15 amino acids in length and an
o¡set of three was synthesized according to the primary sequence of
PLY on cellulose paper as described [15]. This library was incubated
with 1 Wg PLY-5 in PBS containing 2.5% skim milk powder. After
intensive washing a secondary peroxidase conjugated goat anti-mouse
Ig antibody (Jackson Laboratories) was used. Spots were visualized
using ECL (Amersham). As control, the library was probed with the
secondary antibody only. For con¢rmation of the presumable epitope,
a soluble peptide (ECTGLAWEWWRT) was synthesized using an
ABI peptide synthesizer and Fmoc chemistry.
3. Results
The neutralizing mAb PLY-5 had been previously shown to
recognize an epitope within a C-terminal fragment of pneu-
molysin [8]. To further characterize this epitope we tested
PLY-5 for crossreactivity with other members of the thiol-
activated toxin family. As shown in Fig. 1, PLY-5 reacted
in immunoblot with puri¢ed PLY as well as SLO, LLO and
SLY. Furthermore, PLY-5 detected PFO and the proteolytic
fragments of PFO containing the conserved undecapeptide
(data not shown). Reactivity of PLY-5 to additional thiol-
activated toxins, such as cereolysin O, tetanolysin, alveolysin,
thuringiolysin O, ivanolysin, seeligerolysin and botulinolysin,
was studied using bacterial lysates. In all cases except botu-
linolysin, a band of the appropriate molecular weight was
observed (data not shown) indicating reactivity against a de-
terminant that is highly conserved amongst the thiol-activated
toxins. As speci¢city control K-hemolysin of Staphylococcus
aureus or supernatant from a culture of hemolytic E. coli
was used. Both are known to produce other types of mem-
brane-damaging bacterial toxins. As expected, no reactivity of
PLY-5 was observed with these hemolysins (data not shown).
In order to precisely map the epitope that is recognized by
PLY-5 we used a library of overlapping peptides synthesized
as spots on cellulose paper which covered the entire amino
acid sequence of pneumolysin. Binding was detected with a
peroxidase-conjugated secondary antibody and developed by
chemiluminescence (Fig. 2). Spots of minor intensity were al-
ready visible when the library was probed with the secondary
antibody alone (Fig. 2A, upper panel). These spots might
represent unspeci¢c binding or crossreactions of the secondary
antibody. Despite this, the epitope of PLY-5 could be as-
signed unambiguously. Four strong spots were observed
only when PLY-5 was included in the assay (142^145, Fig.
Fig. 1. Immunoblot assays of di¡erent thiol-activated toxins. 500 ng
of puri¢ed PLY, SLO, LLO and SLY were incubated with 1 Wg of
PLY-5 followed by the respective peroxidase-labeled secondary anti-
body. Blots were developed by the chemiluminescence method.
Fig. 2. Epitope mapping of PLY-5. A: Pep-scan analysis of PLY-5.
As a background control peptides covering the whole sequence of
PLY bound on nitrocellulose paper were incubated with a peroxi-
dase-labeled secondary antibody and developed by chemilumines-
cence (upper panel). The nitrocellulose paper was stripped after-
wards and incubated with PLY-5 followed by the secondary
antibody. The strongest signals were observed with peptides 142^145
(lower panel), these signals were absent in the control. Sequences of
the respective peptides are given below. B: Blocking of anti-hemo-
lytic activity of PLY-5 with the soluble form of the Trp-rich pep-
tide.
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2A, lower panel). The amino acid sequences of these four
spots are given below the images in Fig. 2A and the minimal
epitope recognized by PLY-5 that was deduced from this se-
quence information should consist of WEWWRT. Thus, the
mAb PLY-5 binds to an epitope within the conserved unde-
capeptide as already suggested by the reactivity with almost
all thiol-activated toxins.
In order to con¢rm the epitope mapping we tested whether
PLY-5 could be blocked by a peptide containing the presum-
able epitope (ECTGLAWEWWRT). In a conventional he-
molysis neutralization assay 1 Wg of PLY-5 was found to be
neutralizing for 2 HU of PLY, 2 HU of SLO and 4 HU of
LLO. This anti-hemolytic activity of PLY-5 could be blocked
by preincubation with the soluble peptide (Fig. 2B and data
not shown). Thus, the reactivity of PLY-5 with the soluble
peptide con¢rmed the epitope mapping results obtained with
the solid phase assay.
The undecapeptide was postulated to be involved in mem-
brane binding of these toxins, therefore PLY-5 could be used
as a probe to test this hypothesis. Since PLY-5 does not dis-
tinguish between members of the thiol-activated toxin family
we could use toxins where the appropriate reagents were avail-
able. First, toxin binding to SRBC membranes was studied by
£ow cytometry. SLO was preincubated with PLY-5 or 2-5B, a
neutralizing antibody that does not interfere with binding.
Then SRBC were added under standard hemolysis assay con-
ditions and the binding of the antibody-toxin complex was
measured with FITC-conjugated secondary antibodies. Fig.
3A demonstrates that binding of SLO to SRBC was clearly
inhibited by PLY-5, while the complex between 2-5B and
toxin could still bind. This indicates that neutralization by
PLY-5 is due to inhibition of toxin binding to membranes,
which is consistent with the above hypothesis.
Upon binding and intercalation of the toxin into a mem-
brane the undecapeptide should no longer be accessible to
antibodies. This was found to be the case. When SLO was
incubated with SRBC on ice to avoid polymerization and
lysis, the toxin could no longer be recognized by PLY-5
whereas positive staining was obtained with 2-5B under these
circumstances (Fig. 3B). Similar results were obtained using
LLO (Fig. 3C and data not shown) or SLY (data not shown)
as toxin.
These ¢ndings were corroborated by quantitation of toxin
binding in the presence or absence of PLY-5 to SRBC ghosts.
Immunoblot revealed that thiol-activated toxins bind rapidly
to the SRBC vesicles and can be recovered in the pellet frac-
tion after centrifugation. In contrast, toxins preincubated with
PLY-5 no longer bound to the membranes and remained in
the supernatant fraction (Fig. 4) thus con¢rming the results
obtained by cyto£uorometry.
4. Discussion
The neutralizing antibody PLY-5 recognizes an epitope
within the undecapeptide that is conserved amongst all the
thiol-activated cytolysins. This was already suggested by the
reactivity with most members of this toxin family tested so
far. Only in immunoblots from supernatants of C. botulinum
no reactivity with PLY-5 could be detected. This might be due
to low expression of botulinolysin, which depends very
strongly on culture conditions and also varies to a high extent
in di¡erent stains. In addition, amino acid analysis of botu-
linolysin suggests that this protein might be very di¡erent
from the other members of this toxin family [16]. Unambigu-
ously, the epitope of PLY-5 could be identi¢ed by epitope
mapping using overlapping peptides and blocking studies
with a synthetic undecapeptide. This motif has been shown
by mutagenesis experiments to be essential for the hemolytic
activity [4,13].
Based on crystallographic data and other functional studies
a model had been suggested that places this motif at the
membrane proximal tip of the molecule during binding to
the host cell membrane and subsequently intercalates into
the lipid bilayer [5^7]. Based on the three-dimensional struc-
ture a model was proposed in which the undecapeptide is
involved in the formation of a hydrophobic pocket that is
Fig. 3. Analysis of toxin-binding by £ow cytometry. A: SRBC were
incubated with SLO-antibody complexes obtained under standard
neutralization conditions. Binding was observed with 2-5B but not
when PLY-5 was used. B: SLO was preincubated with SRBC on ice
followed by the respective antibody. Fluorescence staining was posi-
tive for the 2-5B antibody but not for PLY-5, indicating that the
PLY-5 epitope is not recognized after the toxin had bound to
SRBC membranes. C: LLO was incubated with SRBC on ice. Bind-
ing was analyzed with an anti-LLO rabbit polyclonal serum fol-
lowed by FITC anti-rabbit IgG. When LLO was preincubated with
PLY-5, no staining was observed, indicating that PLY-5 prevented
toxin binding to SRBC membranes. In contrast, when LLO was not
incubated with PLY-5 (control) binding could be detected.
Fig. 4. Toxin binding analyses by immunoblot. 100 ng toxin (LLO
or PLY) was incubated with SRBC ghosts without preincubation
with PLY-5 (3PLY-5) or after preincubation with PLY-5 (+PLY-
5). Membranes were harvested by ultracentrifugation. Supernatant
(SN) and pellet (P) were applied onto a SDS polyacrylamide gel.
Samples without added SRBC were used as control (S). The gels
were blotted and stained with anti-LLO rabbit polyclonal IgG.
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able to bind cholesterol. Upon binding, this motif is supposed
to undergo a conformational change [7,17,18]. The inhibition
of toxin binding to membranes by PLY-5 is consistent with
this idea as is the fact that the epitope is no longer available to
the antibody after the toxin has bound.
Our ¢ndings are in agreement with the model suggested by
Rossjohn et al. on the binding of thiol-activated cytolysins [5]
and extend previous studies using either mAbs or biophysical
means [7^10]. They appear to be in contradiction with a study
using monoclonal antibodies raised against the undecapeptide
itself [11]. In this study no inhibition of hemolysis by these
antibodies was found, whereas the toxin was recognized in
immunoblot and ELISA. Antibodies against peptides might
bind to native antigens with low a⁄nities. Since a membrane-
seeking molecule might undergo conformational changes
when it is bound to the hydrophobic surface of plastic, reac-
tivity of an antibody in ELISA and recognition in solution
might be di¡erent. On the other hand, PLY-5 was raised
against the native molecule and by de¢nition has to bind to
an area of the molecule that is exposed in solution. Therefore
it is likely that the antibody is of high a⁄nity. The property of
PLY-5 to recognize such an epitope and to inhibit membrane
binding of all thiol-activated toxins renders this antibody not
only of biological but also of therapeutic interest.
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